Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia
Richard J Auchus,Oksana Hamidi,Rosario Pivonello,Irina Bancos,Gianni Russo,Selma F Witchel,Andrea M Isidori,Patrice Rodien,Umasuthan Srirangalingam,Florian W Kiefer,Henrik Falhammar,Deborah P Merke,Nicole Reisch,Kyriakie Sarafoglou,Gordon B Cutler Jr,Julia Sturgeon,Eiry Roberts,Vivian H Lin,Jean L Chan,Robert H Farber,CAHtalyst Adult Trial Investigators,Leen Antonio,Ralitsa Robeva,Syed A Imran,Jan Cap,Jerome Bertherat,Olivier Chabre,Justine Cristante,Delphine Drui,Claire Briet,Frederic Illous,Philippe Touraine,Jacques Young,Jörg Bojunga,Zoe Efstathiadou,Gregory Kaltsas,Stylianos Tsagarakis,Alina German,Gilberta Giacchetti,Dario De Alcubierre,Davide Ferrari,Riccardo Pofi,Mario Maggi,Uberto Pagotto,Luca Persani,Chiara Simeoli,Marta D'Amico,Marianna Rita Stancampiano,Carmen Bucolo,Carla Scaroni,Lucyna Bednarek-Papierska,Marek Ruchala,Grzegorz Sokolowski,Duarte Pignatelli,Miquel Angel Mangas Cruz,Manuel Luque Ramirez,Ana Maria Cristina Carasel,Safwaan Adam,Aled Rees,Aiyappa Biddanda,Xin He,Laura J Chalmers,Patricia Y Fechner,Eric Felner,Luigi R Garibaldi,Jessica Abramowitz,Amy Shah,Sasan Mirfakhraee,Erik A Imel,Mimi S Kim,Kanthi Krishna,Chienying Liu,Karen Loechner,Deborah Merke,Lee Ann Keener,Alyson K Myers,Ron S Newfield,Natalie J Nokoff,Maamoun Salam,Maria G Vogiatzi,Stuart A Weinerman,Selma Feldman Witchel,Mabel Yau
DOI: https://doi.org/10.1056/NEJMoa2404656
2024-08-08
Abstract:Background: Adrenal insufficiency in patients with classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) is treated with glucocorticoid replacement therapy. Control of adrenal-derived androgen excess usually requires supraphysiologic glucocorticoid dosing, which predisposes patients to glucocorticoid-related complications. Crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, lowered androstenedione levels in phase 2 trials involving patients with CAH. Methods: In this phase 3 trial, we randomly assigned adults with CAH in a 2:1 ratio to receive crinecerfont or placebo for 24 weeks. Glucocorticoid treatment was maintained at a stable level for 4 weeks to evaluate androstenedione values, followed by glucocorticoid dose reduction and optimization over 20 weeks to achieve the lowest glucocorticoid dose that maintained androstenedione control (≤120% of the baseline value or within the reference range). The primary efficacy end point was the percent change in the daily glucocorticoid dose from baseline to week 24 with maintenance of androstenedione control. Results: All 182 patients who underwent randomization (122 to the crinecerfont group and 60 to the placebo group) were included in the 24-week analysis, with imputation of missing values; 176 patients (97%) remained in the trial at week 24. The mean glucocorticoid dose at baseline was 17.6 mg per square meter of body-surface area per day of hydrocortisone equivalents; the mean androstenedione level was elevated at 620 ng per deciliter. At week 24, the change in the glucocorticoid dose (with androstenedione control) was -27.3% in the crinecerfont group and -10.3% in the placebo group (least-squares mean difference, -17.0 percentage points; P<0.001). A physiologic glucocorticoid dose (with androstenedione control) was reported in 63% of the patients in the crinecerfont group and in 18% in the placebo group (P<0.001). At week 4, androstenedione levels decreased with crinecerfont (-299 ng per deciliter) but increased with placebo (45.5 ng per deciliter) (least-squares mean difference, -345 ng per deciliter; P<0.001). Fatigue and headache were the most common adverse events in the two trial groups. Conclusions: Among patients with CAH, the use of crinecerfont resulted in a greater decrease from baseline in the mean daily glucocorticoid dose, including a reduction to the physiologic range, than placebo following evaluation of adrenal androgen levels. (Funded by Neurocrine Biosciences; CAHtalyst ClinicalTrials.gov number, NCT04490915.).